The First AI Medical Device That Can Detect All Major Skin Cancers Just Received FDA Approval

Key Points:

  • FDA clearance for DermaSensor as the first AI-powered medical device for skin cancer detection.
  • Implications for primary care physicians, promising improved skin cancer detection rates and enhancing patient care outcomes.
  • The potential for a wider reach and long-term monitoring capabilities, poised to revolutionize skin cancer detection and management.



With over 5 million cases flagged annually in the U.S., accurately diagnosing this disease is critical to patient survival. DermaSensor, an AI-powered medical marvel is primed to change the way skin cancer is diagnosed. On January 17, 2024, the US Food and Drug Administration (FDA) gave its nod to DermaSensor, making it the first of its kind to identify the top three skin cancers—melanoma, basal cell carcinoma, and squamous cell carcinoma.


DermaSensor, Inc., the company behind this innovation, harnesses elastic scattering spectroscopy (ESS) to scrutinize suspicious lesions at a cellular level. Priced at $199 monthly for five patients or $399 for unlimited use, it is set to shake up the medical landscape. With a proactive second opinion within seconds, DermaSensor manages to change the skin cancer detection space.

A full day AI course crammed into 18 mins of

  New Video of Tesla Optimus Bot Walking  

  Elon Musk’s Optimus humanoid robot, showcased by Tesla, was



Prompt Engineering Guides



©2024 The Horizon